Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Fiscal Year: January - December
Organon & Co. (OGN), listed on the NYSE, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $7.14 per share, offering investors a clear view of its current market value. Organon & Co. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 3.73, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Organon & Co. also offers a dividend yield of 1.12%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Organon & Co. (OGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Organon & Co. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Organon & Co., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Organon & Co. is 2.39, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Organon & Co. (OGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Organon & Co. (OGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Organon & Co. (OGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Organon & Co.. To access the full SS Score, consider upgrading your subscription.
Organon & Co. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 3.73. Investors should compare these metrics with industry peers to gauge whether Organon & Co. is outperforming or underperforming within its sector.
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.
Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, a...
Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.
Organon & Co. ( OGN) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP an...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this ...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.
Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 p...
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings...
Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplano...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufa...
Organon remains a buy as the stock trades at distressed valuations despite stable fundamentals and progress on debt reduction. OGN's Women's Health and Biosimilars segments drive growth, offsetting re...
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines...
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new produc...
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of R...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to report second quarter 2025 results and host conference call on August 5, 2025.
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal s...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 853.67M | 11.74% | Est @11.7% |
| 2026 | 943.33M | 10.50% | Analyst x3 |
| 2027 | 1,113.67M | 18.06% | Analyst x3 |
| 2028 | 1,190.50M | 6.90% | Analyst x2 |
| 2029 | 1,275.00M | 7.10% | Analyst x1 |
| 2030 | 1,326.64M | 4.05% | Est @4.1% |
| 2031 | 1,373.90M | 3.56% | Est @3.6% |
| 2032 | 1,418.31M | 3.23% | Est @3.2% |
| 2033 | 1,460.75M | 2.99% | Est @3.0% |
| 2034 | 1,499.30M | 2.64% | Est @2.6% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 548.00M | 1.00 | 548.00M |
| 2024A | 764.00M | 1.00 | 764.00M |
| 2025E | 853.67M | 1.08 | 791.82M |
| 2026E | 943.33M | 1.16 | 811.60M |
| 2027E | 1.11B | 1.25 | 888.74M |
| 2028E | 1.19B | 1.35 | 881.23M |
| 2029E | 1.28B | 1.46 | 875.40M |
| 2030E | 1.33B | 1.57 | 844.87M |
| 2031E | 1.37B | 1.69 | 811.58M |
| 2032E | 1.42B | 1.83 | 777.12M |
| 2033E | 1.46B | 1.97 | 742.39M |
| 2034E | 1.50B | 2.12 | 706.78M |
| Terminal | 28.94B | 2.12 | 13.64B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.